0.00
100.00%
-0.86
Acelrx Pharmaceuticals Inc stock is currently priced at $0.00, with a 24-hour trading volume of 0.
It has seen a -100.00% decreased in the last 24 hours and a -100.00% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.8386 pivot point. If it approaches the $0.7007 support level, significant changes may occur.
Acelrx Pharmaceuticals Inc Stock (ACRX) Financials Data
Acelrx Pharmaceuticals Inc (ACRX) Revenue 2024
ACRX reported a revenue (TTM) of $2.82 million for the quarter ending December 31, 2021, a -47.97% decline year-over-year.
Acelrx Pharmaceuticals Inc (ACRX) Net Income 2024
ACRX net income (TTM) was -$21.36 million for the quarter ending September 30, 2023, a -145.15% decrease year-over-year.
Acelrx Pharmaceuticals Inc (ACRX) Cash Flow 2024
ACRX recorded a free cash flow (TTM) of -$19.10 million for the quarter ending September 30, 2023, a +38.90% increase year-over-year.
Acelrx Pharmaceuticals Inc (ACRX) Earnings per Share 2024
ACRX earnings per share (TTM) was -$2.23 for the quarter ending September 30, 2023, a -142.48% decline year-over-year.
Acelrx Pharmaceuticals Inc Stock (ACRX) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Angotti Vincent J. | Chief Executive Officer |
Sep 11 '23 |
Buy |
0.80 |
10,000 |
7,950 |
91,805 |
Palmer Pamela P | Chief Medical Officer |
Aug 25 '23 |
Sale |
1.09 |
7,442 |
8,104 |
30,753 |
Palmer Pamela P | Chief Medical Officer |
Aug 24 '23 |
Sale |
1.17 |
9,514 |
11,131 |
38,195 |
Acelrx Pharmaceuticals Inc Stock (ACRX) Latest News
About Acelrx Pharmaceuticals Inc
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is based in Hayward, California.
Cap:
|
Volume (24h):